In the post hoc analysis of the PETACC-8 study, which evaluated the effectiveness of adding cetuximab to adjuvant treatment in patients diagnosed with stage III colon cancer, a significant increase in the risk of relapse and poor DFS was detected in codon 12 mutations and a borderline significant increase in codon 13 mutations [ 66 , 67 ].
← all excerpts
A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications.
1
—
—